Canakinumab shows superior efficacy and safety over anakinra in male patients with VEXAS syndrome, a multicenter study finds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback